Faron Pharmaceuticals Oy
LSE:FARN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Max Healthcare Institute Ltd
NSE:MAXHEALTH
|
IN |
FARN's latest stock split occurred on Aug 7, 2019
The company executed a 5000-for-4999 stock split, meaning that for every 4999 shares held, investors received 5000 new shares.
Before the split, FARN traded at 106.5 per share. Afterward, the share price was about 106.
The adjusted shares began trading on Aug 7, 2019. This was the only stock split in FARN's history.
Global
Stock Splits Monitor
| Date | Company | Split | Pre-Split Price | Post-Split Price | |
|---|---|---|---|---|---|
|
Apr 23, 2026
|
|
Red Sky Energy Ltd
ASX:ROG
|
5-for-4
x1.25
|
0.002 0.0016 AUD | 0.002 0.002 AUD |
|
Apr 23, 2026
|
J
|
Jiusheng Electric Co Ltd
SZSE:301082
|
1-for-1
x1
|
17.33 13.2508 CNY | 12.9 12.9 CNY |
|
Apr 23, 2026
|
S
|
Saudee Group Bhd
KLSE:SAUDEE
|
1-for-10
/10
|
0.01 0.1 MYR | 0.09 0.09 MYR |
|
Apr 23, 2026
|
|
Focus Technology Co Ltd
SZSE:002315
|
1-for-1
x1
|
44.3999 33.4538 CNY | 32 32 CNY |
|
Apr 22, 2026
|
S
|
Sharetronic Data Technology Co Ltd
SZSE:300857
|
1-for-1
x1
|
304.5701 217.2101 CNY | 260.76 260.76 CNY |
ROG
002315
Faron Pharmaceuticals Oy
Glance View
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company, which engages in the development of treatment for acute organ traumas, vascular damage, and cancer immunotherapy. The company is headquartered in Turku, Lansi-Suomen and currently employs 37 full-time employees. The company went IPO on 2015-11-17. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The firm has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. The company is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. The company may be used alone or in combination with other immune checkpoint molecules.
